Seegene, a leading South Korean company which provides a total solution for PCR molecular diagnostics, has announced an agreement with Werfen, a worldwide leader in Specialised Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem Business.

The collaboration will consist of the joint development of syndromic qPCR assays suitable for the Spanish and Portuguese healthcare systems, including assays for sexually transmitted infections and drug resistance. Seegene has a long-term relationship with Werfen, based in Barcelona, Spain.

The companies are discussing the co-development of qPCR assays at Werfen's OEM Technology Center in Lliçà d´Amunt, Barcelona, Spain.

These discussions follow an agreement Seegene reached in March with Israel's top diagnostic company, Hylabs.

Seegene's OneSystem Business aims to share its syndromic quantitative PCR technologies, and digitalised development system (SGDDS) which enables less experienced researchers to develop assays. 

Through this partnership, Spain and Portugal will have the technology and know-how to develop and manufacture syndromic qPCR assays, establishing infrastructure that will enable a rapid response to future pandemics without relying on foreign products and resources.